Impact of Standing Orders Optimization

Human Papilloma Virus Clinical Trial

Official title:

Evaluating the Impact of Optimizing the Use of HPV Vaccine Standing Orders in Primary Care Clinics

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05742386
• Other study ID #: IMPACTP1SO
• Secondary ID: 5P01CA250989-02
• Status: Recruiting
• Phase: N/A
• Start date: February 22, 2023
• Est. completion date: July 31, 2026

Study information

• Verified date: May 2024
• Source: UNC Lineberger Comprehensive Cancer Center
• Contact: Katherine Kritikos
• Phone: +1 (919) 962-6327
• Email: kkritikos[@]unc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial will look at the impact of optimizing human papillomavirus (HPV) vaccine standing orders. The research team will work with primary care clinics. Some clinics will receive communication training. Other clinics will receive the same training and tools for increasing the use of their standing orders.

Description:

The researchers will conduct a cluster randomized clinical trial. The trial will look at the impact of optimizing HPV vaccine standing orders. The recruitment goal for the trial is 34 clinics in healthcare systems, including 9 rural-serving clinics. The researchers will randomize clinics using simple randomization (1:1). Some clinics will receive a communication training. Other clinics will receive a communication training and tools for optimizing the use of their standing orders. The researchers will use medical record data to compare changes in HPV vaccination among children ages 9-12. Clinics will be followed for 24 months. The researchers will also use survey data to compare HPV vaccine communication and implementation of standing orders among clinical staff. The study will engage clinical staff. Researchers will not have direct contact with children or their families.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 34
• Est. completion date: July 31, 2026
• Est. primary completion date: June 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 9 Years to 12 Years

Eligibility

This trial will enroll clinics and intervene with clinical staff. We will use vaccination data from children and survey data from clinical staff to evaluate intervention effectiveness. We will not enroll children or interact with them directly. Inclusion Criteria

Clinics are eligible if they:

• provide HPV vaccine to children ages 9-12
• have standing orders for HPV vaccination approved but not routinely used or be willing to adopt them prior to the start of the trial
• have rates of HPV vaccination (=1 dose) below 72%, boys and girls combined

Children's medical records will be eligible to be included in the dataset if children:

• are between the ages of 9-12 years at baseline
• are attributed to a participating clinic at 12- or 24-month follow-up Clinical staff's survey data will be eligible to be included in the dataset if clinical staff complete the follow-up survey. Exclusion Criteria

Clinics are excluded if they:

• do not provide HPV vaccine to children ages 9-12
• do not have standing orders for HPV vaccination or are not willing to adopt them prior to the start of the trial
• have rates of HPV vaccination (=1 dose) above 72%, boys and girls combined
• have hosted an AAT workshop in the previous 3 years or are part of current HPV vaccine communication trainings
• have quality improvement efforts to change HPV vaccine standing orders during the trial

Children's medical records will not be eligible to be included in the dataset if children:

• are not between the ages of 9-12 years at baseline
• are not attributed to a participating clinic at 12- or 24-month follow-up
• are receiving hospice/palliative care, are pregnant, or have a history of HPV vaccine contraindications Clinical staff's survey data will be not eligible to be included in the dataset if clinical staff do not complete the follow-up survey.

Related Conditions & MeSH terms

• Human Papilloma Virus
• Papilloma

Intervention

Behavioral:
• Communication training
Clinics will host an AAT workshop. A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
• Communication training enhanced with standing orders optimization
Clinics will host an AAT workshop, as in the other trial arm. Clinic representatives will attend working meetings on putting HPV vaccine standing orders into clinic workflow. Clinics will then orient their staff to the standing orders. Finally, clinic representatives will discuss their use of standing orders in a learning collaborative.

Locations

Country	Name	City	State
United States	The University of North Carolina at Chapel Hill	Chapel Hill	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
UNC Lineberger Comprehensive Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HPV vaccination (=1 dose), 9-12 year olds	Proportion of unvaccinated children who initiate the HPV vaccine series between baseline and 12-month follow-up, among those who were ages 9-12 at baseline.	from baseline to 12 months
Secondary	HPV vaccination (=1 dose), 9-12 year olds	Proportion of unvaccinated children who initiate the HPV vaccine series between 13- and 24-month follow-up, among those who were ages 9-12 at 13 months.	from 13 months to 24 months
Secondary	HPV vaccination (=2 doses), 9-12 year olds	Proportion of unvaccinated children who complete the HPV vaccine series between baseline and 12-month follow-up, among those who were ages 9-12 at baseline.	from baseline to 12 months
Secondary	HPV vaccination (=2 doses), 9-12 year olds	Proportion of unvaccinated children who complete the HPV vaccine series between 13- and 24-month follow-up, among those who were ages 9-12 at 13 months.	from 13 months to 24 months
Secondary	Standing orders attitude rating	Positive attitude toward using HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating more positive attitudes.	up to 6 months
Secondary	Standing orders norms rating	Norms in favor of using HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating more supportive norms.	up to 6 months
Secondary	Standing orders self-efficacy rating	Confidence about using HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating higher confidence.	up to 6 months
Secondary	Standing orders adoption rating	Adoption of HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating greater adoption.	up to 6 months
Secondary	Standing orders acceptability rating	Acceptability of HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating higher acceptability.	up to 6 months
Secondary	Standing orders appropriateness rating	Appropriateness of HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating greater appropriateness.	up to 6 months
Secondary	Standing orders role rating	Understanding of role under HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating better understanding of role.	up to 6 months
Secondary	Standing orders feasibility rating	Feasibility of HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating greater feasibility.	up to 6 months
Secondary	Standing orders sustainability rating	Sustainability of HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating greater sustainability.	up to 6 months
Secondary	Estimated time spent on recommendations	Time spent on HPV vaccine recommendations will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 0-99 minutes, with higher values indicating more time spent.	up to 6 months
Secondary	Estimated recommendation frequency, 9-10 year olds	Frequency of recommending HPV vaccine for children ages 9 or 10 will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating more frequent recommendations.	up to 6 months
Secondary	Estimated recommendation frequency, 11-12 year olds	Frequency of recommending HPV vaccine for children ages 11 or 12 will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating more frequent recommendations.	up to 6 months
Secondary	Recommendation attitudes rating	Positive attitudes toward recommending HPV vaccine for ages children ages 9 or 10 years will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating more positive recommendation attitudes.	up to 6 months
Secondary	Recommendation self-efficacy rating	Confidence in recommending HPV vaccine for children ages 9 or 10 will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating higher recommendation confidence.	up to 6 months
Secondary	Recommendation norms rating	Norms in favor of recommending HPV vaccine for children ages 9 or 10 will be measured by one item on the survey, taken by clinical staff two months after attending the AAT. The range for this measure will be 1 to 5, with higher values indicating more supportive norms.	up to 6 months
Secondary	Recommendation intentions rating	Intentions to recommend HPV vaccine for children ages 9 or 10 will be measured by one item on the survey, taken by clinical staff two months after attending the AAT The range for this measure will be 1 to 5, with higher values indicating higher recommendation intentions.	up to 6 months

External Links

•   University of North Carolina Lineberger Comprehensive Cancer Center Clinical Trials